TegoScience Inc Cash Flow Conversion Efficiency
TegoScience Inc cash flow conversion efficiency. Based on the latest financial reports, TegoScience Inc (191420) has a cash flow conversion efficiency ratio of -0.016x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-700.37 Million ≈ $-474.63K USD) by net assets (₩43.60 Billion ≈ $29.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of TegoScience Inc (2015–2025)
Cash flow conversion efficiency of TegoScience Inc from 2015 to 2025. This chart illustrates how TegoScience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 191420 stock price and chart for real-time trading data and today's change.
TegoScience Inc Cash Flow Conversion Ratio Explained
TegoScience Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
TegoScience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TegoScience Inc ranked by their cash flow conversion efficiency. Also see TegoScience Inc (191420) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rubicon Water Ltd
AU:RWL
|
0.155x |
|
Summa Silver Corp
V:SSVR
|
-0.009x |
|
Inspirisys Solutions Limited
NSE:INSPIRISYS
|
0.188x |
|
Rhone Ma Holdings Bhd
KLSE:5278
|
0.003x |
|
MANUKA RESOURCES LTD
F:6M0A
|
N/A |
|
Siyata Mobile Inc
NASDAQ:SYTA
|
-0.355x |
|
Wisher Industrial Co Ltd
TW:1465
|
-0.178x |
|
AlphaTime Acquisition Corp Ordinary Shares
NASDAQ:ATMC
|
-0.001x |
Annual Cash Flow Conversion Efficiency for TegoScience Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of TegoScience Inc from 2015 to 2025. Review 191420 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩50.33 Billion ≈ $34.11 Million |
₩-3.07 Billion ≈ $-2.08 Million |
-0.061x | -162.02% |
| 2024-12-31 | ₩49.86 Billion ≈ $33.79 Million |
₩-1.16 Billion ≈ $-785.84K |
-0.023x | -35.59% |
| 2023-12-31 | ₩46.33 Billion ≈ $31.39 Million |
₩-794.61 Million ≈ $-538.49K |
-0.017x | -180.12% |
| 2022-12-31 | ₩48.60 Billion ≈ $32.93 Million |
₩1.04 Billion ≈ $705.01K |
0.021x | +126.95% |
| 2021-12-31 | ₩48.47 Billion ≈ $32.85 Million |
₩457.25 Million ≈ $309.87K |
0.009x | -63.89% |
| 2020-12-31 | ₩48.99 Billion ≈ $33.20 Million |
₩1.28 Billion ≈ $867.16K |
0.026x | +2916.76% |
| 2019-12-31 | ₩47.82 Billion ≈ $32.41 Million |
₩41.40 Million ≈ $28.06K |
0.001x | -95.15% |
| 2018-12-31 | ₩46.68 Billion ≈ $31.63 Million |
₩833.88 Million ≈ $565.11K |
0.018x | -77.74% |
| 2017-12-31 | ₩35.71 Billion ≈ $24.20 Million |
₩2.87 Billion ≈ $1.94 Million |
0.080x | -11.57% |
| 2016-12-31 | ₩25.98 Billion ≈ $17.61 Million |
₩2.36 Billion ≈ $1.60 Million |
0.091x | -13.13% |
| 2015-12-31 | ₩25.21 Billion ≈ $17.08 Million |
₩2.63 Billion ≈ $1.78 Million |
0.104x | -- |
About TegoScience Inc
TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.